Drug design with Cdc7 kinase: A potential novel cancer therapy target

Drug Design, Development and Therapy

Volumn , Issue 2, 2008, Pages 255-264

  Sawa, Masaaki ^a   Masai, Hisao ^b  

^a 1 5 5 Minatojima Minamimachi   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

ATP binding pocket; Cdc7 kinase; Cell cycle; DNA damages; Genome stability; Kinase inhibitor; Replication fork

Indexed keywords

2 (2 AMINOPYRIMIDINY 4 YL) 7 (2 FLUOROETHYL) 1,5,6,7 TETRAHYDROPYRROLO[3,2 C]PYRIDINONE; 2 PYRIMIDYL 5 AMIDOTHIOPHENE; 3 AMINOPYRIMIDIN DERIVATIVE; 4 INDAZOLYLPYRIMIDIN 2(1H) ONE; AMINO ACID; CDC7 KINASE; CHECKPOINT KINASE 1; DNA; IMIDAZOLE DERIVATIVE; MINICHROMOSOME MAINTENANCE PROTEIN 2; NMS 354; PHA 767491; PROTEIN KINASE B INHIBITOR; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLOPYRIDINONE COMPOUND; SCAFFOLD PROTEIN; THIENOPYRAZOLE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; DNA DAMAGE; DNA REPLICATION; DNA SYNTHESIS; DOWN REGULATION; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GENOMIC INSTABILITY; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; IC 50; KNOCKOUT GENE; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SEQUENCE HOMOLOGY; STRUCTURE ACTIVITY RELATION; TEMPERATURE SENSITIVE MUTANT;

EID: 67650719017     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Bartek J, Lukas J. 2003. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell, 3:421-429 (Pubitemid 38340288)
2. Cherry M, Williams DH. 2004. Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. Curr Med Chem, 11:663-673 (Pubitemid 38380042)
3. Collins I, Garrett MD. 2005. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol, 5:366-373 (Pubitemid 40932038)
4. Collins I, Workman P. 2006. New approaches to molecular cancer therapeutics. Nat Chem Biol, 2:689-700. (Pubitemid 44764211)
5. Costanzo V, Shechter D, Lupardus PJ, et al. 2003. An ATR- and Cdc7-dependent DNA damage checkpoint that inhibits initiation of DNA replication. Mol Cell, 11:203-213 (Pubitemid 36126601)
6. D'Andrea AD, Grompe M. 2003. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer, 3:23-34.
7. de Cárcer G, de Castro IP, Malumbres M. 2007. Targeting cell cycle kinases for cancer therapy. Curr Med Chem, 14:969-985 (Pubitemid 46672634)
8. Dierov J, Dierova R, Carroll M. 2004. BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell, 5:275-285 (Pubitemid 38402119)
9. Fischer PM, Endicott J, Meijer L. 2003. Cyclin-dependent kinase inhibitors. Prog Cell Cycle Res, 5:235-248
10. Fung AD, Ou J, Bueler S, et al. 2002. A conserved domain of Schizosaccharomyces pombe dfp1(+) is uniquely required for chromosome stability following alkylation damage during S phase. Mol Cell Biol, 22:4477-4490 (Pubitemid 34620386)
11. Gabrielse C, Miller CT, McConnell KH, et al. 2006. A Dbf4p BRCA1 C-terminal-like domain required for the response to replication fork arrest in budding yeast. Genetics, 173:541-555 (Pubitemid 43945877)
12. Hanks SK, Quinn AM, Hunter T. 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science, 241:42-52.
13. Hartwell LH. 1971. Genetic control of the cell division cycle in yeast. II. Genes controlling DNA replication and its initiation. J Mol Biol, 59:183-194
14. Hathaway GM, Traugh JA. 1984. Kinetics of activation of casein kinase II by polyamines and reversal of 2,3-bisphosphoglycerate inhibition. J Biol Chem, 259:7011-7015
15. Im JS, Lee JK. 2008. ATR-dependent activation of p38 MAP kinase is responsible for apoptotic cell death in cells depleted of Cdc7. J Biol Chem, 283:25171-25177
16. Jackson AL, Pahl PM, Harrison K, et al. 1993. Cell cycle regulation of the yeast Cdc7 protein kinase by association with the Dbf4 protein. Mol Cell Biol, 13:2899-2908 (Pubitemid 23133961)
17. Johnston LH, Masai H, Sugino A. 1999. First the CDKs, now the DDKs. Trends Cell Biol, 9:249-252
18. Johnston LH, Thomas AP. 1982. A further two mutants defective in initiation of the S phase in the yeast Saccharomyces cerevisiae. Mol Gen Genet, 186:445-448 (Pubitemid 13231989)
19. Kakusho N, Taniyama C, Masai H. 2008. Identification of stimulators and inhibitors of CDC7 kinase in vitro. J Biol Chem, 283:19211-19218
20. Kim BJ, Kim SY, Lee H. 2007. Identification and characterization of human cdc7 nuclear retention and export sequences in the context of chromatin binding. J Biol Chem, 282:30029-30038 (Pubitemid 350035240)
21. Kim JM, Kakusho N, Yamada M, et al. 2008. Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint. Oncogene, 27:3475-3482 (Pubitemid 351769309)
22. Kim JM, Nakao K, Nakamura K, et al. 2002. Inactivation of Cdc7 kinase in mouse ES cells results in S-phase arrest and p53-dependent cell death. EMBO J, 21:2168-2179 (Pubitemid 34516776)
23. Kitada K, Johnston LH, Sugino T, et al. 1992. Temperature-sensitive cdc7 mutations of Saccharomyces cerevisiae are suppressed by the DBF4 gene, which is required for the G1/S cell cycle transition. Genetics, 131:21-29
24. Leroy V, Bacque E, Conseille E, et al. 2008. New imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7. Patent: WO2008/046982.
25. Lin X, Rico A, Zhou Y, et al. 2005. Substitued thiophene derivatives as anti-cancer agents. Patent: WO2005/095386.
26. Masai H, Miyake T, Arai K. 1995. hsk1+, a Schizosaccharomyces pombe gene related to Saccharomyces cerevisiae CDC7, is required for chromosomal replication. EMBO J, 14:3094-3104
27. Masai H, Sato N, Takeda T, et al. 1999. CDC7 kinase complex as a molecular switch for DNA replication. Front Biosci, 4:D834-40.
28. Masai H, Arai K. 2000. Dbf4 motifs: conserved motifs in activation subunits for Cdc7 kinases essential for S-phase. Biochem Biophys Res Commun, 275:228-232 (Pubitemid 30663656)
29. Masai H, Matsui E, You Z, et al. 2000. Human Cdc7-related kinase complex. In vitro phosphorylation of MCM by concerted actions of Cdks and Cdc7 and that of a criticial threonine residue of Cdc7 by Cdks. J Biol Chem, 275:29042-29052
30. Masai H, Arai K. 2002. Cdc7 kinase complex: a key regulator in the initiation of DNA replication. J Cell Physiol, 190:287-296 (Pubitemid 34111969)
31. Masai H, Taniyama C, Ogino K, et al. 2006. Phosphorylation of MCM4 by Cdc7 kinase facilitates its interaction with Cdc45 on the chromatin. J Biol Chem, 281:39249-39261 (Pubitemid 46041884)
32. Matsumoto S, Ogino K, Noguchi E, et al. 2005. Hsk1-Dfp1/Him1, the Cdc7-Dbf4 kinase in Schizosaccharomyces pombe, associates with Swi1, a component of the replication fork protection complex. J Biol Chem, 280:42536-42542 (Pubitemid 43049210)
33. Menichincheri M, Bargiotti A, Berthelsen J, et al. 2007. Cdc7 kinase inhibitors: 7-Substituted pyrrolopyridinones as potent and orally active antitumor agents [Abstract]. 19th EORTC-NCI-AACR Symposium, October 22-26, San Franscisco, CA, USA. A224.
34. Michelson RJ, Weinert T. 2000. Closing the gaps among a web of DNA repair disorders. Bioessays, 22:966-969
35. Montagnoli A, Santocanale C, Valsasina B, et al. 2008b. A new and potent orally available class of Cdc7 inhibitors with anti-tumor activity [abstract]. AACR 99th Annual Meeting, April 12-16, San Diego, CA, USA. #755.
36. Montagnoli A, Tenca P, Sola F, et al. 2004. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells. Cancer Res, 64:7110-7116 (Pubitemid 39331024)
37. Montagnoli A, Valsasina B, Croci V, et al. 2008a. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol, 4:357-365 (Pubitemid 351693995)
38. Niida H, Nakanishi M. 2006. DNA damage checkpoints in mammals. Mutagenesis, 21:3-9.
39. Noble ME, Endicott JA, Johnson LN. 2004. Protein kinase inhibitors: insights into drug design from structure. Science, 303:1800-1805 (Pubitemid 38374863)
40. Ogi H, Wang CZ, Nakai W, et al. 2008. The role of the Saccharomyces cerevisiae Cdc7-Dbf4 complex in the replication checkpoint. Gene, 414:32-40.
41. Ogino K, Takeda T, Matsui E, et al. 2001. Bipartite binding of a kinase activator activates Cdc7-related kinase essential for S phase. J Biol Chem, 276:31376-31387 (Pubitemid 37385009)
42. Patterson M, Sclafani RA, Fangman WL, et al. 1986. Molecular characterization of cell cycle gene CDC7 from Saccharomyces cerevisiae. Mol Cell Biol, 6:1590-1598 (Pubitemid 16089495)
43. Sclafani RA. 2000. Cdc7p-Dbf4p becomes famous in the cell cycle. J Cell Sci, 13:2111-2117
44. Shafer C, Walter A, Lindvall MK, et al. 2007. Indazole compounds and methods for inhibition of CDC7. Patent: WO2007/124288.
45. Shafer C, Lindvall M, Bellamacina C, et al. 2008. 4-(1H-Indazol-5-yl)-6- phenylpyrimidin-2(1H)-one analogs as potent CDC7 inhibitors. Bioorg Med Chem Lett, 18:4482-4485
46. Sheu YJ, Stillman B. 2006. Cdc7-Dbf4 phosphorylates MCM proteins via a docking site-mediated mechanism to promote S phase progression. Mol Cell, 24:101-113 (Pubitemid 44466677)
47. Snaith HA, Brown GW, Forsburg SL. 2000. Schizosaccharomyces pombe Hsk1p is a potential cds1p target required for genome integrity. Mol Cell Biol, 20:7922-7932
48. Sommariva E, Pellny TK, Karahan N, et al. 2005. Schizosaccharomyces pombe Swi1, Swi3, and Hsk1 are components of a novel S-phase response pathway to alkylation damage. Mol Cell Biol, 25:2770-2784 (Pubitemid 40381639)
49. Sonoda E, Sasaki MS, Buerstedde JM, et al. 1998. Rad51-deficient vertebrate cells accumulate chromosomal breaks prior to cell death. EMBO J, 17:598-608. (Pubitemid 28045499)
50. Takeda T, Ogino K, Tatebayashi K, et al. 2001. Regulation of initiation of S phase, replication checkpoint signaling, and maintenance of mitotic chromosome structures during S phase by Hsk1 kinase in the fission yeast. Mol Biol Cell, 12:1257-1274 (Pubitemid 33044409)
51. Tenca P, Brotherton D, Montagnoli A, et al. 2007. Cdc7 is an active kinase in human cancer cells undergoing replication stress. J Biol Chem, 282:208-215 (Pubitemid 47076589)
52. Tonani R, Bindi S, Fancelli D, et al. 2004. Heterobicyclic pyrazole derivatives as kinase inhibitors. Patent: WO2004/007504.
53. Vanotti E, Amici R, Bargiotti A, et al. 2008. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. J Med Chem, 51:487-501. (Pubitemid 351252277)
54. Vanotti E, Caldarelli M, Cirla A, et al. 2007. Pyridyl- and pyrimidinyl-substitued pyrrole-, thiophene- and furane-derivatives as kinase inhibitors. Patent: WO2007/110344.
55. Varrin AE, Prasad AA, Scholz RP, et al. 2005. A mutation in Dbf4 motif M impairs interactions with DNA replication factors and confers increased resistance to genotoxic agents. Mol Cell Biol, 25:7494-7504
56. Vieth M, Higgs RE, Robertson DH, et al. 2004. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta, 1697:243-257 (Pubitemid 38326776)
57. Warner SL, Gray PJ, Von Hoff DD. 2006. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others. Semin Oncol, 33:436-448
58. Weinreich M, Stillman B. 1999. Cdc7p-Dbf4p kinase binds to chromatin during S phase and is regulated by both the APC and the RAD53 checkpoint pathway. EMBO J, 18:5334-5346 (Pubitemid 29465583)
59. Yamashita N, Kim JM, Koiwai O, et al. 2005. Functional analyses of mouse ASK, an activation subunit for Cdc7 kinase, using conditional ASK knockout ES cells. Genes Cells, 10:551-563 (Pubitemid 40867487)
60. Yoshizawa-Sugata N, Ishii A, Taniyama C, et al. 2005. A second human Dbf4/ASK-related protein, Drf1/ASKL1, is required for efficient progression of S and M phases. J Biol Chem, 280:13062-13070 (Pubitemid 40491130)
61. Zhao C, Chen L, Xu Q, et al. 2005. Synthesis and evaluation of pyridothieno-pyrrimidine as potent and selective CDC7 inhibitor [Abstract]. 229th ACS National Meeting, March 13-17, San Diego, CA, USA. MEDI 141.